Saving newborn lives through early detection of congenital heart diseases
Pouya-Heart the first clinically validated screening device for CHD and CCHD.
Clinically tested on more than 10,000 neonates and children in Iran and India, Pouya-Heart is redefining early cardiac screening. Designed for every stage of childhood, from birth to 12 years, it brings hospital-grade accuracy to both clinics and bedside care.
Pouya-Heart NE
For newborns (0-1 month)
Pouya-Heart
For infants to children (1 month-12 years)
Online Platform
Real-time data acquisition and management
The Story Behind the Innovation
Dr. Amir A. Sepehri
Inventor of Pouya-Heart
"When my own son was diagnosed with congenital heart disease, I saw firsthand how critical early detection is. That experience inspired me to dedicate more than 25 years to developing a simple, reliable screening tool that could protect other children."
For over two decades, Dr. Sepehri has led the scientific development of Pouya-Heart, combining clinical expertise with a deeply personal mission. His work has helped create the first clinically validated early-screening devices for CHD and CCHD, now improving neonatal care in multiple countries.
Clinical Validation & Key Achievements
Clinically Validated Across 10,000+ Newborns and Children
10,000+
Screenings
Validated in multi-center studies across neonatal and pediatric units in Iran and India.
High Diagnostic Accuracy
>97% sensitivity
>97% specificity
Achieved in real-world clinical workflows.
Fast & Non-Invasive
<2 minutes
Screening completed in under 2 minutes, easily performed by nurses or physicians.
Full Pediatric Coverage
Validated for newborns (0-1 month) and children up to 12 years.
Where Our Studies Took Place
Our clinical studies demonstrate strong performance compared to standard neonatal examinations and highlight Pouya-Heart as the first validated early-screening tools for CHD and CCHD.
View Full Clinical StudiesTechnology
Advanced Technology Made Simple for Pediatric Care
Capture
Heart sound signal is recorded using an electronic (digital) stethoscope.
Analyze
Algorithms analyze the acoustic spectral patterns to identify potential abnormalities linked to CHD and CCHD.
Result
A clear screening result appears instantly, and the system can be operated by midwives, nurses, or physicians.
Built on decades of clinical experience, Pouya-Heart transforms traditional auscultation into a precise, data-driven screening tool for early detection of congenital heart disease.
Explore Full TechnologyProducts
Designed for neonatal units, pediatric clinics, private cabinets, mobile teams, and hospitals.
Pouya-Heart NE
Specifically designed for newborns during the critical first month of life.
0-1 month
Pouya-Heart
Optimized for infants and children, supporting early detection throughout childhood.
1 month-12 years
Portable Device
Lightweight, compact, and ideal for clinics, home visits, and outreach programs.
Hospital Cart Device
Designed for neonatal and pediatric wards, with integrated display and stable positioning.
Online Screening Platform
Real-time data acquisition, centralized storage, and secure management for large-scale screening programs.
(Optional) All device versions use the same validated heart sound analysis technology, ensuring consistent quality and accuracy across settings.
Partners & Contact
Bordbar et al. Neonatal Screening Trial
"We accurately and cost-effectively screened for congenital heart malformations and identified cases that standard examinations could not detect."
Source: Published Clinical Study
Kocharian et al. Pediatric Screening Study
"With high sensitivity, specificity and efficiency, the system is recommended to support timely referrals, especially in underserved rural areas."
Source: Published Clinical Study